Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- DLB +11.4%, WIX +11%, GLBE +9.6%, KEYS +9.1%, ZIM +8.8%, VREX +5.8%, QFIN +4.8% (also authorizes new $450 mln share repurchase program), LZB +4.5% (also increases dividend), AZEK +4.4%, SNEX +3.4%, TJX +0.8%
Other news:
- AZTA +8.7% (CEO bought 13967 shares; also moves to S&P 600 from S&P 400)
- SGMO +8.2% (announces FDA clearance of IND application for ST-503)
- FLEX +6.5% (to join S&P MidCap 400)
- ZI +4.9% (CEO bought 492500 shares)
- CON +4.6% (to join S&P SmallCap 600)
- ARGX +4% (Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies)
- HROW +3.2% (Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery)
- LNTH +2% (authorizes $250 mln share repurchase program)
- RXRX +1.9% (Recursion Pharmaceuticals and and Exscientia (EXAI) have officially combined to advance the industrialization of drug discovery)
- LSAK +1.8% (to acquire Recharger for $28 mln)
- VKTX +1.5% (presents results from Phase 2b VOYAGE study)
- HIVE +1.2% (Canaan Secures Follow-On Order from HIVE (HIVE) for 5,000 Avalon A15-194T Miners)
- PATK +1% (declares 3-for-2 stock split)